604 Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial

Authors:
  • AAA. Awada
    A. Awada
  • JDJ.P. Delord
    J.P. Delord
  • NHN. Houédé
    N. Houédé
  • CLC. Lebbe
    C. Lebbe
  • TLT. Lesimple
    T. Lesimple
  • JSJ.H.M. Schellens
    J.H.M. Schellens
  • SRS. Rottey
    S. Rottey
  • NRN. Rejeb
    N. Rejeb
  • ERE. Raymond
    E. Raymond
Publisher website
Google Scholar
Abstract
No abstract available